Tag Archives: Palbociclib

[ad_1] MUNICH – Median survival in patients treated with palbociclib cyclin-dependent inhibitor (CDK) 4/6, an advanced hormone receptor-positive inhibitor (HR +), was improved by 10 months in addition to hormone therapy, randomized …

[ad_1] Massimo Cristofanilli, MD The association palbociclib (Ibrance) and fulvestrant (Faslodex) resulted in a clinically significant benefit in terms of overall survival (OS) in patients with advanced HER2-negative breast cancer presenting with …